Alicja Kalinowska-Lyszczarz
Overview
Explore the profile of Alicja Kalinowska-Lyszczarz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
256
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wojcicka-Frankiewicz A, Pawlak M, Piernik M, Forycka M, Wilkosc-Debczynska M, Wiesik-Szewczyk E, et al.
Lupus
. 2025 Feb;
34(3):270-280.
PMID: 39927750
BackgroundThe mechanism of cognitive dysfunction in systemic lupus erythematosus (SLE) is still not fully understood. Even though many SLE patients present some neurological dysfunction, including various cognitive deficits, neither a...
2.
Gakh O, Wilkins J, Guo Y, Popescu B, Weigand S, Kalinowska-Lyszczarz A, et al.
Acta Neuropathol Commun
. 2024 Sep;
12(1):146.
PMID: 39256864
Multiple sclerosis (MS) is a leading cause of non-traumatic disability in young adults. The highly dynamic nature of MS lesions has made them difficult to study using traditional histopathology due...
3.
Wilkins J, Mangalaparthi K, Netzel B, Sherman W, Guo Y, Kalinowska-Lyszczarz A, et al.
Front Mol Neurosci
. 2024 Sep;
17:1448215.
PMID: 39234409
Background: Multiple sclerosis (MS) is a demyelinating disease of the central nervous system characterized by increased inflammation and immune responses, oxidative injury, mitochondrial dysfunction, and iron dyshomeostasis leading to demyelination...
4.
Kania K, Pawlak M, Forycka M, Wilkosc-Debczynska M, Michalak S, Lukaszewska A, et al.
Neurol Neurochir Pol
. 2024 Feb;
58(2):176-184.
PMID: 38324117
Introduction: Cognitive impairment occurs from the earliest stages of multiple sclerosis (MS) and progresses over time. The introduction of disease modifying therapies (DMTs) has changed the prognosis for MS patients,...
5.
Guo Y, Endmayr V, Zekeridou A, McKeon A, Leypoldt F, Hess K, et al.
Acta Neuropathol
. 2024 Feb;
147(1):31.
PMID: 38310187
Anti-glial fibrillary acidic protein (GFAP) meningoencephalomyelitis (autoimmune GFAP astrocytopathy) is a new autoimmune central nervous system (CNS) disease diagnosable by the presence of anti-GFAP autoantibodies in the cerebrospinal fluid and...
6.
Kania K, Ambrosius W, Kozubski W, Kalinowska-Lyszczarz A
Front Neurol
. 2023 Jul;
14:1222574.
PMID: 37503514
Objective: Over the last few decades clinicians have become aware that cognitive impairment might be a major cause of disability, loss of employment and poor quality of life in patients...
7.
Kania K, Ambrosius W, Dyczkowska K, Kozubski W, Kalinowska-Lyszczarz A
Neurol Neurochir Pol
. 2023 May;
57(3):289-296.
PMID: 37144905
Introduction: Several studies have suggested the possibility that disease prodromes might occur months or even years before a multiple sclerosis diagnosis. Objectives: To describe the profile of prodromal symptoms and...
8.
Jackson-Tarlton C, Londono D, Lucchinetti C, Duffy D, Weigand S, Tillema J, et al.
Mult Scler Relat Disord
. 2023 Apr;
73:104676.
PMID: 37019056
Background: MS is the most common CNS inflammatory demyelinating disease. Plasma exchange (PLEX) has well-demonstrated efficacy in acute corticosteroid-refractory attacks of demyelination but identifying the factors that predict favorable PLEX...
9.
Kalinowska-Lyszczarz A, Tillema J, Tobin W, Guo Y, Weigand S, Metz I, et al.
Ann Clin Transl Neurol
. 2023 Feb;
10(3):339-352.
PMID: 36759436
Objective: In this observational study on a cohort of biopsy-proven central nervous system demyelinating disease consistent with MS, we examined the relationship between early-active demyelinating lesion immunopattern (IP) with subsequent...
10.
Dyczkowska K, Kalinowska-Lyszczarz A
Neurol Neurochir Pol
. 2023 Feb;
57(1):90-100.
PMID: 36727546
The purpose of this literature review was to summarise relevant findings regarding the clinical management of multiple sclerosis (MS) in the COVID-19 pandemic, with the focus on patient risks, and...